

Philogen announces Philochem Patent Upheld

Philogen, a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, announces that Philochem's European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries ("ESAC 2+1" technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office.

The patent entitled "Production of Encoded Chemical Libraries", granted on May 23rd 2018, claims inventions that are instrumental for the isolation and discovery of novel ligands for biologically relevant targets.

The European Patent Office decision came in response to a notice of opposition filed by NuEvolution A/S, now part of Amgen, on February 23rd 2019. The decision rejected all opposition grounds filed by NuEvolution and all claims were maintained.

"We are pleased that the European Patent Office has upheld the validity of this important patent" said Prof. Dario Neri, CEO of Philogen, "The confirmation of these inventions strengthens our patent portfolio and emphasizes the international value and appeal of our IP. We encourage companies focused on the discovery of important ligands from Encoded Chemical Libraries to join forces and discuss licensing agreements with us as we have the ability and the track-record to show that we can provide innovative solutions in finding ligands against difficult or undruggable targets"

About Philogen

Philogen is a Swiss-Italian, fully integrated, biotech company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and small organic ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical candidates in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is listed on the Italian stock exchange and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com and www.philochem.com.

For more information please contact:

Philogen

Dr. Christian Lizak (Business Development) / Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

christian.lizak@philogen.com / emanuele.puca@philogen.com

-

Consilium Strategic Communications

Mary-Jane Elliott, Davide Salvi, Lucie Foster

Philogen@consilium-comms.com